Page 2112 - Williams Hematology ( PDFDrive )

2086 Part XII: Hemostasis and Thrombosis Chapter 121: Acquired Qualitative Platelet Disorders 2087

15. Rich JB: The efficacy and safety of aprotinin use in cardiac surgery. Ann Thorac Surg 48. Li X, Fries S, Li R, et al: Differential impairment of aspirin-dependent platelet cycloox-
66(5 Suppl):S6–S11, 1998. ygenase acetylation by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A
16. Antithrombotic Trialists Collaboration: Collaborative meta-analysis of randomised tri- 111(47):16830–16835, 2014.
als of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in 49. Kearney PM, Baigent C, Godwin J, et al: Do selective cyclo-oxygenase-2 inhibitors and
high risk patients. BMJ 324(7329):71–86, 2002. traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombo-
17. Seshasai SR, Wijesuriya S, Sivakumaran R, et al: Effect of aspirin on vascular and non- sis? Meta-analysis of randomised trials. BMJ 332(7553):1302–1308, 2006.
vascular outcomes: Meta-analysis of randomized controlled trials. Arch Intern Med 50. Antman EM, Bennett JS, Daugherty A, et al: Use of nonsteroidal antiinflammatory
172(3):209–216, 2012. drugs: An update for clinicians: A scientific statement from the American Heart Asso-
18. Raju N, Sobieraj-Teague M, Hirsh J, et al: Effect of aspirin on mortality in the primary ciation. Circulation 115(12):1634–1642, 2007.
prevention of cardiovascular disease. Am J Med 124(7):621–629, 2011. 51. Solomon SD, Wittes J, Finn PV, et al: Cardiovascular risk of celecoxib in 6 randomized
19. Bartolucci AA, Tendera M, Howard G: Meta-analysis of multiple primary prevention placebo-controlled trials: The cross trial safety analysis. Circulation 117(16):2104–2113,
trials of cardiovascular events using aspirin. Am J Cardiol 107(12):1796–1801, 2011. 2008.
20. Kallmann R, Nieuwenhuis HK, de Groot PG, et al: Effects of low doses of aspirin, 10 mg 52. Trelle S, Reichenbach S, Wandel S, et al: Cardiovascular safety of non-steroidal anti-
and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PGF1 alpha inflammatory drugs: Network meta-analysis. BMJ 342:c7086, 2011.
excretion in healthy subjects. Thromb Res 45:355, 1987. 53. McGettigan P, Henry D: Cardiovascular risk and inhibition of cyclooxygenase: A sys-
21. Nakajima H, Takami H, Yamagata K, Kariya K, Tamai Y, Nara H: Aspirin effects on tematic review of the observational studies of selective and nonselective inhibitors of
colonic mucosal bleeding. Dis Colon Rectum 40:1484, 1997. cyclooxygenase 2. JAMA 296(13):1633–1644, 2006.
22. Mielke CH Jr: Aspirin prolongation of the template bleeding time: Influence of venos- 54. Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N, Emberson
tasis and direction of incision. Blood 60(5):1139–1142, 1982. J, Merhi A, et al: Vascular and upper gastrointestinal effects of non-steroidal anti-
23. Hirsh J, Salzman EW, Harker L, et al: Aspirin and other platelet active drugs. Relation- inflammatory drugs: Meta-analyses of individual participant data from randomised
ship among dose, effectiveness, and side effects. Chest 95(2 Suppl):12S–18S, 1989. trials. Lancet 382(9894):769–779, 2013.
24. Page IH: Salicylate damage to the gastric mucosal barrier. N Engl J Med 276:1307, 1967. 55. Schmidt M, Christiansen CF, Mehnert F, et al: Non-steroidal anti-inflammatory drug
25. Leonards JR, Levy G: The role of dosage form in aspirin-induced gastrointestinal bleed- use and risk of atrial fibrillation or flutter: Population based case-control study. BMJ
ing. Clin Pharmacol 8:400, 1969. 343:d3450, 2011.
26. Baigent C, Blackwell L, Collins R, et al: Aspirin in the primary and secondary preven- 56. Hinz B, Cheremina O, Brune K: Acetaminophen (paracetamol) is a selective
tion of vascular disease: Collaborative meta-analysis of individual participant data from cyclooxygenase-2 inhibitor in man. FASEB J 22(2):383–390, 2008.
randomised trials. Lancet 373(9678):1849–1860, 2009. 57. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspi-
27. Stuart MJ, Gross SJ, Elrad H, Graeber JE: Effects of acetylsalicylic-acid ingestion on rin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
maternal and neonatal hemostasis. N Engl J Med 307(15):909–912, 1982. Lancet 348(9038):1329–1339, 1996.
28. Ferraris VA, Ferraris SP, Lough FC, Berry WR: Preoperative aspirin ingestion increases 58. McTavish D, Faulds D, Goa KL: Ticlopidine. An updated review of its pharmacology
operative blood loss after coronary artery bypass grafting. Ann Thorac Surg 45(1):71– and therapeutic use in platelet-dependent disorders. Drugs 40(2):238–259, 1990.
74, 1988. 59. Geiger J, Brich J, Honig-Liedl P, et al: Specific impairment of human platelet P2Y(AC)
29. Sethi GK, Copeland JG, Goldman S, et al: Implications of preoperative administration ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler
of aspirin in patients undergoing coronary artery bypass grafting. Department of Vet- Thromb Vasc Biol 19(8):2007–2011, 1999.
erans Affairs Cooperative Study on Antiplatelet Therapy. J Am Coll Cardiol 15(1):15–20, 60. Daniel JL, Dangelmaier C, Jin J, et al: Molecular basis for ADP-induced platelet acti-
1990. vation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem
30. Horlocker TT, Wedel DJ, Offord KP: Does preoperative antiplatelet therapy increase the 273(4):2024–2029, 1998.
risk of hemorrhagic complications associated with regional anesthesia? Anesth Analg 61. Farid NA, Kurihara A, Wrighton SA: Metabolism and disposition of the thienopyridine
70(6):631–634, 1990. antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol
31. Kitchen L, Erichson RB, Sideropoulos H: Effect of drug-induced platelet dysfunction 50(2):126–142, 2010.
on surgical bleeding. Am J Surg 143(2):215–217, 1982. 62. Yusuf S, Zhao F, Mehta SR, et al: Effects of clopidogrel in addition to aspirin in
32. Devereaux PJ, Mrkobrada M, Sessler DI, et al; POISE-2 Investigators: Aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med
patients undergoing noncardiac surgery. N Engl J Med 370(16):1494–1503, 2014. 345(7):494–502, 2001.
33. Kennedy BM: Aspirin and surgery—A review. Ir Med J 77(11):363–369, 1984. 63. De Caterina R, Sicari R, Bernini W, et al: Benefit/risk profile of combined antiplatelet
34. Livio M, Benigni A, Vigano G, et al: Moderate doses of aspirin and risk of bleeding in therapy with ticlopidine and aspirin. Thromb Haemost 65(5):504–510, 1991.
renal failure. Lancet 1(8478):414–416, 1986. 64. Helft G, Osende JI, Worthley SG, et al: Acute antithrombotic effect of a front-loaded
35. Gaspari F, Vigano G, Orisio S, et al: Aspirin prolongs bleeding time in uremia by a regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb
mechanism distinct from platelet cyclooxygenase inhibition. J Clin Invest 79(6): Vasc Biol 20(10):2316–2321, 2000.
1788–1797, 1987. 65. Parodi G, Valenti R, Bellandi B, et al: Comparison of prasugrel and ticagrelor loading
36. Chesebro JH, Fuster V, Elveback LR, et al: Trial of combined warfarin plus dipyrida- doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of
mole or aspirin therapy in prosthetic heart valve replacement: Danger of aspirin com- Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 61(15):1601–1606, 2013.
pared with dipyridamole. Am J Cardiol 51(9):1537–1541, 1983. 66. Collet JP, Hulot JS, Pena A, et al: Cytochrome P450 2C19 polymorphism in young
37. Kobrinsky NL, Israels ED, Gerrard JM, et al: Shortening of bleeding time by patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet
1-deamino-8-D-arginine vasopressin in various bleeding disorders. Lancet 1(8387): 373(9660):309–317, 2009.
1145–1148, 1984. 67. Mega JL, Close SL, Wiviott SD, et al: Cytochrome p-450 polymorphisms and response
38. Lethagen S, Rugarn P: The effect of DDAVP and placebo on platelet function and pro- to clopidogrel. N Engl J Med 360(4):354–362, 2009.
longed bleeding time induced by oral acetyl salicylic acid intake in healthy volunteers. 68. Jernberg T, Payne CD, Winters KJ, et al: Prasugrel achieves greater inhibition of plate-
Thromb Haemost 67(1):185–186, 1992. let aggregation and a lower rate of non-responders compared with clopidogrel in
39. Kasmeridis C, Apostolakis S, Lip GY: Aspirin and aspirin resistance in coronary artery aspirin-treated patients with stable coronary artery disease. Eur Heart J 27(10):
disease. Curr Opin Pharmacol 13(2):242–250, 2013. 1166–1173, 2006.
40. Grosser T, Fries S, Lawson JA, et al: Drug resistance and pseudoresistance: An unin- 69. Brandt JT, Payne CD, Wiviott SD, et al: A comparison of prasugrel and clopidogrel
tended consequence of enteric coating aspirin. Circulation 127(3):377–385, 2013. loading doses on platelet function: Magnitude of platelet inhibition is related to active
41. Floyd CN, Ferro A: Mechanisms of aspirin resistance. Pharmacol Ther 141(1):69–78, metabolite formation. Am Heart J 153(1):66 e9–e16, 2007.
2014. 70. Wiviott SD, Braunwald E, McCabe CH,; TRITON-TIMI 38 Investigators: Prasugrel ver-
42. Catella-Lawson F, Reilly MP, Kapoor SC, et al: Cyclooxygenase inhibitors and the anti- sus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357(20):2001–
platelet effects of aspirin. N Engl J Med 345(25):1809–1817, 2001. 2015, 2007.
43. Mielke CH Jr, Kahn SB, Muschek LD, et al: Effects of zomepirac on hemostasis in 71. Hass WK, Easton JD, Adams HP Jr, et al: A randomized trial comparing ticlopidine
healthy adults and on platelet function in vitro. J Clin Pharmacol 20(5–6 Pt 2):409–417, hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopi-
1980. dine Aspirin Stroke Study Group. N Engl J Med 321(8):501–507, 1989.
44. Lamberts M, Lip GY, Hansen ML, et al: Relation of nonsteroidal anti-inflammatory 72. Gent M, Blakely JA, Easton JD, et al: The Canadian American Ticlopidine Study (CATS)
drugs to serious bleeding and thromboembolism risk in patients with atrial fibrilla- in thromboembolic stroke. Lancet 1(8649):1215–1220, 1989.
tion receiving antithrombotic therapy: A nationwide cohort study. Ann Intern Med 73. Mataix R, Ojeda E, Perez MC, Jimenez S: Ticlopidine and severe aplastic anaemia.
161(10):690–698, 2014. Br J Haematol 80(1):125–126, 1992.
45. Thomas P, Hepburn B, Kim HC, Saidi P: Nonsteroidal anti-inflammatory drugs in the 74. Garnier G, Taillan B, Pesce A, et al: Ticlopidine and severe aplastic anaemia. Br J Hae-
treatment of hemophilic arthropathy. Am J Hematol 12(2):131–137, 1982. matol 81(3):459–460, 1992.
46. McIntyre BA, Philp RB, Inwood MJ: Effect of ibuprofen on platelet function in normal 75. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al: Thrombotic thrombocy-
subjects and hemophiliac patients. Clin Pharmacol Ther 24(5):616–621, 1978. topenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med
47. Ragni MV, Miller BJ, Whalen R, Ptachcinski R: Bleeding tendency, platelet function, 128(7):541–544, 1998.
and pharmacokinetics of ibuprofen and zidovudine in HIV(+) hemophilic men. Am J 76. Steinhubl SR, Tan WA, Foody JM, Topol EJ: Incidence and clinical course of thrombotic
Hematol 40(3):176–182, 1992. thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT

Kaushansky_chapter 121_p2073-2096.indd 2087 9/18/15 10:28 AM